Holen Sie sich die Stockscreener-App
90.13
1.66%
1.47
Handel nachbörslich:
90.20
0.07
+0.08%
Schlusskurs vom Vortag:
$88.66
Offen:
$88.92
24-Stunden-Volumen:
941.54K
Relative Volume:
0.81
Marktkapitalisierung:
$22.64B
Einnahmen:
$3.26B
Nettoeinkommen (Verlust:
$-1.45B
KGV:
-15.35
EPS:
-5.871
Netto-Cashflow:
$1.18B
1W Leistung:
-2.10%
1M Leistung:
-6.78%
6M Leistung:
-9.39%
1J Leistung:
-13.62%
1-Tages-Spanne:
$88.45
$90.72
1-Wochen-Bereich:
$88.45
$98.60
52-Wochen-Spanne:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
90.13 | 22.64B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-08 | Eingeleitet | Argus | Hold |
| 2026-09-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2026-05-27 | Hochstufung | UBS | Neutral → Buy |
| 2026-05-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
BioNTech SE stock gains as Berenberg lifts price target after recent pullback - AD HOC NEWS
BioNTech stock heads into the open after a 2.9 percent Nasdaq drop - AD HOC NEWS
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech (NASDAQ: BNTX) investor moves to sell shares; filing shows how big - Stock Titan
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
BioNTech's Leadership Exodus Looms as Vaccine Franchise Holds While Oncology Ambitions Take a Hit - aktiencheck.de
BioNTech's Split-Screen Week: A Trial Halted, a Vaccine Approved, and a Pipeline Under the Microscope - aktiencheck.de
BioNTech SEADR Peer Comparison – Compare with Others - Value Research
Why is BioNTech stock down 7.8% today? - tradersunion.com
BioNTech SEADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
BioNTech SEADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BioNTech stock tumbles 10% on cancer trial termination - Investing.com
BioNTech Shares Drop 6.6% After Board Terminates Colorectal Cancer Vaccine Study - TechStock²
BioNTech Stock Falls. It Can’t Match Moderna’s mRNA Cancer Vaccine Win. - Barron's
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Barchart.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FDA approves Pfizer-BioNTech COVID vaccine targeting XFG variant - investing.com
global market • stocks • Vienna Stock Exchange - wienerborse.at
Should You Buy Moderna Stock Following Its Cancer Breakthrough? - TradingView
BioNTech (BNTX) Financial Update: EPS Comes in Below Forecast in the Available Record; Price Reaction: Shares Move 4.40% Lower on the DayDividend Cut Risk - dars.gov.et
BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing - Barchart.com
BioNTech (BNTX) Financial Update: EPS Comes in Below Forecast in the Available Record; Price Reaction: Shares Move 4.40% Lower on the DayLow Estimate Range - dars.gov.et
Market Wrap: Stocks Fall as Industrials and Utilities Decline - Morningstar
BioNTech’s New HIV RNA Vaccine Trial: What Investors Should Watch Now - TipRanks
BioNTech jumps $5.1 billion in premarket; analyst target now just 8% higher - TechStock²
Is Cancer the Next Breakthrough for Moderna After COVID-19? - TradingView
Moderna ascends more than 175% from cancer vaccine breakthrough - Mugglehead Investment Magazine
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - Barchart.com
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biontech Se Adr-Aktie (BNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer |
Oct 08 '26 |
Sale |
92.31 |
27,000 |
2,492,483 |
36,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 07 '26 |
Sale |
95.86 |
24,000 |
2,300,633 |
63,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 06 '26 |
Sale |
96.81 |
21,000 |
2,032,995 |
87,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 05 '26 |
Sale |
97.23 |
72,000 |
7,000,646 |
108,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 02 '26 |
Sale |
96.72 |
17,000 |
1,644,323 |
180,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 01 '26 |
Sale |
97.46 |
17,000 |
1,656,745 |
197,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 30 '26 |
Sale |
98.12 |
32,000 |
3,139,850 |
214,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 29 '26 |
Sale |
98.26 |
34,000 |
3,340,809 |
246,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 28 '26 |
Sale |
98.47 |
34,000 |
3,347,919 |
280,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 25 '26 |
Sale |
98.69 |
27,000 |
2,664,581 |
314,209 |
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):